Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.
Also called NCT07090161
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Vanda Pharmaceuticals
- Registry
-
NCT07090161
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07090161. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-15 (actual); primary completion 2026-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
- Condition
- Hypertension
- Condition
- Uncontrolled Hypertension
- Intervention (Drug)
- iloperidone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Vanda Pharmaceuticals
Record details
- Record id
cardio:ct-nct07090161- Content hash
843696df29805074454faa40faa423b1cf0e86f717f03196b0cd8bb2e1691bec